Worldwide Clinical Trials has released a survey report on the perceptions of large and midsize contract research organizations (CROs) within the pharmaceutical and biotech sectors. The survey, which included a range of clinical trial sponsors from the U.S. and Europe, highlights concerns about large CROs’ performance and service delivery due to complex market dynamics.
Key findings from the survey indicate:
1. The claim from large CROs of being a “one-stop-shop” is viewed by 80% of respondents as not cost-effective, and it often fails to provide seamlessly integrated services.
2. Instability within large CROs has made 50% of respondents hesitant to partner with them, citing issues like project team disruptions, lack of access to top talent, and poor service delivery.
3. Almost 70% of respondents reported receiving a “B” team when large CROs promised an “A” team, raising doubts about these CROs’ ability to offer consistent support across all customer sizes.
The survey suggests that the industry anticipates a shift in outsourcing activity from large CROs to midsize CROs, with expectations of a 5% net gain over the next three years, as sponsors increasingly seek partnerships prioritizing customer service, communication, and adaptability.
Peter Benton, Worldwide’s president and CEO, emphasizes the importance of these attributes for the success of clinical research programs. Samir Shah of Shah Pharma Consulting Services LLC further supports the findings, noting the need for tailored solutions based on the client’s operating model.
Overall, the report from Worldwide Clinical Trials illuminates the industry’s changing needs and preferences, suggesting a demand for more flexible, responsive, and customized CRO services to effectively navigate the changing clinical landscape.